Larimar Therapeutics Inc. (NASDAQ: LRMR)
$9.98
-0.6000 ( -5.67% ) 172.2K
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Market Data
Open
$9.98
Previous close
$10.58
Volume
172.2K
Market cap
$639.93M
Day range
$9.88 - $10.57
52 week range
$2.18 - $13.68
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 60 | May 09, 2024 |
10-q | Quarterly Reports | 51 | May 09, 2024 |
def | Proxies and info statements | 15 | Apr 29, 2024 |
ars | Annual reports | 1 | Apr 29, 2024 |
pre | Proxies and info statements | 15 | Apr 12, 2024 |
8-k | 8K-related | 14 | Mar 14, 2024 |
10-k | Annual reports | 82 | Mar 14, 2024 |
8-k | 8K-related | 82 | Mar 11, 2024 |
8-k | 8K-related | 17 | Feb 16, 2024 |
4 | Insider transactions | 2 | Feb 16, 2024 |